RxDoctor Payments Data

Ann Arcese

Gerontology · Saint Louis, MONPI 1982959466

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Lilly USA, LLC at 49.6% of the total. 2025 is the largest year on record at $316, 3.3 times the $96 reported in 2022.

$902in general payments, 2019–2025

Across 49 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$448
  • Novo Nordisk$149
  • GSK$129
  • Pfizer$80
  • Boehringer Ingelheim$38
  • Abbott$23
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$902100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$902 in reported general payments places this provider in the 70th percentile of 175 gerontology providers in Missouri.

See all gerontology providers in Missouri

Medicare billing

Part B allowed, 2024
$14,717
Medicare patients
86
Services billed
144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide12$20,998
EliquisApixaban17$20,516
JardianceEmpagliflozin11$17,133
MounjaroTirzepatide13$16,048
ArexvyRsvpref3 Antigen/As01e/Pf14$3,779
Bupropion XlBupropion Hcl54$1,856
Omeprazole74$1,237
Gabapentin61$830
Azelastine Hcl29$773
Rosuvastatin Calcium67$717
SynthroidLevothyroxine Sodium12$649
Fluticasone Propionate35$538
Albuterol Sulfate HfaAlbuterol Sulfate25$486
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav54$463
Atorvastatin Calcium82$454

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$149$20,99812 claims
PfizerEliquis$80$20,51617 claims
Boehringer IngelheimJardiance$38$17,13311 claims
Lilly USA, LLCMounjaro$448$16,04813 claims
GSKArexvy$129$3,77914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 175 gerontology providers in Missouri.

Other gerontology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →